Immuneering Corporation beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging +22.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.26 | $-0.27 | -3.9% | Miss | |
| Q1 FY26 | $-0.30 | $-0.21 | +30.0% | Beat | |
| Q4 FY25 | $-0.31 | $-0.18 | +41.9% | Beat |
Back to IMRX overview · IMRX holders · IMRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.